[go: up one dir, main page]

DE60134147D1 - Träger in partikelform zur verbesserung der oral- absorption von wikstoffen - Google Patents

Träger in partikelform zur verbesserung der oral- absorption von wikstoffen

Info

Publication number
DE60134147D1
DE60134147D1 DE60134147T DE60134147T DE60134147D1 DE 60134147 D1 DE60134147 D1 DE 60134147D1 DE 60134147 T DE60134147 T DE 60134147T DE 60134147 T DE60134147 T DE 60134147T DE 60134147 D1 DE60134147 D1 DE 60134147D1
Authority
DE
Germany
Prior art keywords
oral absorption
sums
particulate
improvement
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60134147T
Other languages
English (en)
Inventor
Philippe Maincent
Nathalie Ubrich
Claude Vigneron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Farmaceuticos Rovi SA
Original Assignee
Laboratorios Farmaceuticos Rovi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Farmaceuticos Rovi SA filed Critical Laboratorios Farmaceuticos Rovi SA
Application granted granted Critical
Publication of DE60134147D1 publication Critical patent/DE60134147D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE60134147T 2000-07-07 2001-07-05 Träger in partikelform zur verbesserung der oral- absorption von wikstoffen Expired - Lifetime DE60134147D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0008902A FR2811227A1 (fr) 2000-07-07 2000-07-07 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
PCT/FR2001/002159 WO2002003960A1 (fr) 2000-07-07 2001-07-05 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs

Publications (1)

Publication Number Publication Date
DE60134147D1 true DE60134147D1 (de) 2008-07-03

Family

ID=8852251

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60134147T Expired - Lifetime DE60134147D1 (de) 2000-07-07 2001-07-05 Träger in partikelform zur verbesserung der oral- absorption von wikstoffen

Country Status (17)

Country Link
US (1) US8052998B2 (de)
EP (1) EP1313453B1 (de)
JP (1) JP5175017B2 (de)
KR (1) KR20030038655A (de)
CN (1) CN1440277A (de)
AT (1) ATE395906T1 (de)
AU (1) AU2002218745A1 (de)
BR (1) BRPI0112080B1 (de)
CA (1) CA2415414C (de)
DE (1) DE60134147D1 (de)
DK (1) DK1313453T3 (de)
ES (1) ES2305121T3 (de)
FR (1) FR2811227A1 (de)
MX (1) MXPA03000193A (de)
PT (1) PT1313453E (de)
RU (1) RU2003103596A (de)
WO (1) WO2002003960A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257744B2 (en) * 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
EP2060253A1 (de) * 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Pharmazeutische Formen zur Freisetzung von Wirkstoffen
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
ATE347358T1 (de) * 2003-04-17 2006-12-15 Jallal Messadek Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
EP1730516A1 (de) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Verfahren und vorrichtung zur bewertung pharmazeutischer zusammensetzungen
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
EP1848410A4 (de) * 2005-02-17 2011-11-09 Medivas Llc Zusammensetzungen zur ausgabe von polymerteilchen und anwendungsverfahren dafür
MX2007013486A (es) * 2005-04-27 2008-03-14 Jallal Messadek Combinaciones de insulinas.
US8652504B2 (en) 2005-09-22 2014-02-18 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2178518A2 (de) * 2007-07-13 2010-04-28 Bend Research, Inc Nanopartikel mit ionisierbaren und schwach wasserlöslichen zellulose-polymeren
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
EP2213282A1 (de) * 2009-01-30 2010-08-04 Laboratorios Farmaceuticos Rovi, S.A. Pharmazeutische Formen zur Freisetzung von Wirkstoffen
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
US9101547B2 (en) * 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
DE102012019029A1 (de) 2012-09-27 2014-03-27 Alf Lamprecht Arzneiformulierungen zur oralen Gabe von therapeutischen Substanzen und Verfahren zur Herstellung
CA3015172A1 (en) 2016-02-18 2017-08-24 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
US20180235899A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
KR20240041285A (ko) * 2021-06-01 2024-03-29 프리보 테크놀로지스, 인코포레이티드 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
EP0535937B2 (de) * 1991-10-01 2008-05-21 Takeda Chemical Industries, Ltd. Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4220782A1 (de) * 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
ES2159726T3 (es) * 1995-03-10 2001-10-16 Roche Diagnostics Gmbh Formas de administracion farmaceuticas que contienen polipeptidos, en forma de microparticulas, y procedimiento para su fabricacion.
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
FR2769853B1 (fr) * 1997-10-21 2000-01-28 Prographarm Lab Nouveau procede d'obtention de microspheres et les produits ainsi realises
NZ511614A (en) * 1998-11-12 2003-12-19 Smithkline Beecham P Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin
WO2000043044A1 (en) * 1999-01-19 2000-07-27 The Children's Hospital Of Philadelphia Compositions and methods for controlled delivery of virus vectors

Also Published As

Publication number Publication date
JP5175017B2 (ja) 2013-04-03
BR0112080A (pt) 2003-05-06
FR2811227A1 (fr) 2002-01-11
PT1313453E (pt) 2008-07-16
CA2415414A1 (fr) 2002-01-17
MXPA03000193A (es) 2004-09-13
ES2305121T3 (es) 2008-11-01
KR20030038655A (ko) 2003-05-16
EP1313453A1 (de) 2003-05-28
US8052998B2 (en) 2011-11-08
RU2003103596A (ru) 2004-08-20
US20050013866A1 (en) 2005-01-20
AU2002218745A1 (en) 2002-01-21
EP1313453B1 (de) 2008-05-21
DK1313453T3 (da) 2008-09-22
CN1440277A (zh) 2003-09-03
CA2415414C (fr) 2011-08-23
JP2004502720A (ja) 2004-01-29
BRPI0112080B1 (pt) 2017-01-24
WO2002003960A1 (fr) 2002-01-17
ATE395906T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
DE60134147D1 (de) Träger in partikelform zur verbesserung der oral- absorption von wikstoffen
BR9809025B1 (pt) polìmero anfótero, e, veìculo cosmeticamente aceitável.
IT1317727B1 (it) Sostanze che assorbono i raggi ultravioletti costituite dabenzotriazoli aventi una aumentata durata.
BR9915457B1 (pt) composições de moldagem, uso e artigo.
ID30325A (id) Komposisi polimer emisi rendah
FI20002539L (fi) Hepatosyyttiin kohdentuva polyetyleeniglykohaaroittunut poly-L-lysiinipolymeerigeenikantaja
ATE298202T1 (de) Kaugummi mit eingekapseltem schleifaktivem füllstoff
BR0308486A (pt) Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
DE60041150D1 (de) Dekodierung von matrixsensoren mit mikrokugeln
DE69930446T8 (de) Flüssigkeitsabgedichtete, elastische Lagerung
MXPA03001372A (es) Vulcanizado termoplastico orientado.
DZ3181A1 (fr) Dispositif de stockage.
ATE437311T1 (de) Scheibenbremse
BG106316A (en) Ambroxol-containing lozenge
AR017436A1 (es) Una composicion farmaceutica en una dispersion molecular con biodisponibilidad mejorada
BR0115410B1 (pt) transportador de pessoal, e, segmento de corrente de transportador.
NL193406B (nl) Kunstmest met een hoge hardheid en opslagstabiliteit, alsmede de bereiding hiervan.
ATE225391T1 (de) Waschmittelzusammensetzung mit wasserunlöslichem, entfärbungshemmendem polymerwirkstoff
IT1303235B1 (it) Corpo portante per dispositivi tensionatori, in particoalre di cinghiedi trasmissione.
FR2719528B1 (fr) Dispositif de blocage latéral de chariots placés en file notamment dans des compartiments d'engins mobiles.
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması
ITTO20010230V0 (it) Luce, in particolare per veicoli.
ES1043602Y (es) Transportin para animales mejorado.
NO995089D0 (no) Tillaeringsmetoder i binaere systemer
ES1043049Y (es) Mesa de centro.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition